左西孟旦联合常规抗心力衰竭药物治疗顽固性心力衰竭的临床效果  

Clinical effect of levosimendan combined with conventional anti-heart failure drugs in the treatment of refractory heart failure

作　　者：郑雯 ZHENG Wen(Cardiovascular Department of Internal Medicine,Liaoyang City Central Hospital,Liaoyang,Liaoning,111000)

机构地区：[1]辽宁省辽阳市中心医院心血管内科,辽宁辽阳111000

出　　处：《实用临床医药杂志》2020年第12期22-24,28,共4页Journal of Clinical Medicine in Practice

摘　　要：目的探讨左西孟旦联合常规抗心力衰竭药物治疗顽固性心力衰竭的临床疗效。方法选取本院心血管内科住院治疗的84例顽固性心力衰竭患者,随机分为对照组和研究组,每组42例。对照组给予常规抗心力衰竭药物治疗,研究组在对照组基础上联合左西孟旦治疗。比较2组治疗前后心脏超声检查相关指标、血清氨基末端脑利钠肽前体(NT-proBNP)、心肌肌钙蛋白T(cTnT)和超敏C反应蛋白(hs-CRP)水平变化,并评估2组近期疗效。结果2组治疗后每搏输出量(SV)、左室射血分数(LVEF)、心脏指数(CI)均显著升高(P<0.05),且研究组治疗后LVEF、SV和CI均高于对照组,差异有统计学意义(P<0.05)。2组治疗后血清NT-proBNP、cTnT和hs-CRP水平较治疗前显著下降(P<0.05),且研究组显著低于对照组(P<0.05);研究组和对照组临床总有效率分别为92.86%、76.19%,2组差异有统计学意义(P<0.05)。结论左西孟旦联合常规抗心力衰竭药物能显著改善顽固性心力衰竭患者的心功能,减轻心肌损伤和炎症反应,提高临床疗效。Objective To explore the clinical efficacy of levosimendan combined with conventional anti-heart failure drugs in the treatment of refractory heart failure.Methods A total of 84 patients with refractory heart failure who were hospitalized in the cardiovascular department of our hospital were randomly divided into control group and study group,with 42 cases in each group.The control group was given conventional anti-heart failure drugs,while the study group was additionally treated with levosimendan on the basis of the control group.Before and after treatment,changes in indicators of cardiac ultrasound examination,serum N-terminal pronatriuretic peptide(NT-proBNP),cardiac troponin T(cTnT)and hypersensitive C reactive protein(hs-CRP)levels were compared between the two groups,and short-term efficacy of two groups was compared.Results Left ventricular ejection fraction(LVEF),stroke volume(SV)and cardiac index(CI)in the two groups were significantly higher(P<0.05),and LVEF,SV and CI in the study group were higher than those in the control group(P<0.05).The levels of NT-proBNP,cTnT and hs-CRP in the two groups were significantly lower than those before treatment(P<0.05),and the study group was significantly lower than the control group(P<0.05).The total clinical effective rate of the study group and the control group were 92.86%and 76.19%,respectively,which showed a significant difference(P<0.05).Conclusion Levosimendan combined with conventional anti-heart failure drugs can significantly improve the heart function of patients with refractory heart failure,reduce myocardial injury and inflammatory response,and increase the clinical efficacy.

关 键 词：顽固性心力衰竭 左西孟旦 心脏超声 氨基末端脑利钠肽前体 心肌肌钙蛋白T 超敏C反应蛋白 

分 类 号：R541.6[医药卫生—心血管疾病]